基于临床科研信息共享系统的慢性乙型肝炎证治规律研究
|
摘要
背景和目的
我国是慢性乙型肝炎高发区，其流行性广，难于彻底根治,预计我国有乙肝病毒携带者0.93亿以上,现症慢性乙型肝炎患者约2千万以上,其中10-20%可发展为肝硬化，1-5%可演变为肝癌，不仅造成巨大的经济损失和资源消耗，也给人们的身体健康和社会生产力造成严重威胁，是我国目前面临的最严重的公共卫生问题之一。中医药是我国人民的宝贵财富，是古代人民智慧的结晶，是我国最具原创性的领域。加强中医药防治慢性乙型肝炎的研究，对提高我国慢性乙型肝炎防治能力和水平具有十分重要的意义。中医治疗传统中医肝病有系统的中医理论基础、悠久的历史，积累了大量的临床经验，自从上世纪60年开始中医药就广泛的运用于乙肝病毒引起的相关疾病的临床治疗，并进行了大量的临床与实验研究。当今世界正向大数据时代迈进，数据作为一种巨大的资源，通过数据来解决问题的创新模式已越来越得到重视。将大数据理论及其研究方法应用到中医药的临床与科研中，将会给中医学带来革命性的变化。
本研究通过构建肝病临床科研信息共享系统，形成临床科研一体化的基础信息平台，以海量临床信息为基础，开展基于真实世界的临床实际数据的科学研究，可以从中发现中医临床的经验、规律和问题，验证中医临床疗效，发现中医临床疗效相关的规律。本研究以慢性乙型肝炎为研究对象，分析探讨慢性乙型肝炎中医证候分布特点及辨治用药规律，为建立标准化规范化的中医诊疗模式提供参考，为规范慢性乙型肝炎中医辨证论治提供依据，提高临床诊疗水平。
方法本研究分为三个部分。
第一部分：肝病临床科研信息共享系统构建研究
首先从教材、标准、文献三个方面为基础进行临床术语收集，建立中医肝病临床基本术语集，再基于临床基本术语和肝病中医诊疗方案制定结构化电子病历模板，形成肝病结构化电子病历模板集，并充分整合医院的信息化资源，利用现代信息与网络技术，构建数字化、信息化、网络化的中医药临床数据支撑平台与管理服务共享体系，即临床科研信息共享系统，使其具备临床诊疗信息全程收集、整理和分析能力，实现基于临床实际数据的科学研究。
第二部分：基于共享系统的慢性乙型肝炎证候规律研究
基于临床科研信息共享系统，应用结构化电子病历采集慢性乙型肝炎患者的住院信息。采集数据来源于2002年-2013年诊断为慢性乙型肝炎的住院患者，共1200例。对采集的数据进行解析、转换、清洗、处理，抽取所需要的数据导入数据仓库。利用临床科研一体化技术平台及复杂网络技术，对基本信息、舌象、脉象、症状、中医证候的分布进行聚类分析，对常见证型与症状、舌象、脉象之间进行关联分析，利用SPSS17.0软件进行统计分析，探讨慢性乙型肝炎中医证候分布规律。第三部分：基于共享系统的慢性乙型肝炎用药规律研究
在第二部分的数据采集的基础上将采集的中药数据进行分析处理，利用临床科研一体化技术平台及复杂网络技术，对中药使用频率、药物性味归经等进行了统计分析，并分析中药与中医证候的关联性，利用SPSS17.0软件进行统计分析，探讨慢性乙型肝炎中药用药规律。结果
第一部分：肝病临床科研信息共享系统构建研究
1形成了标准规范的中医肝病临床基本术语集，包括主体临床术语26种，属性术语10种，其中肝病常见症状类术语69个。
2基于中医肝病诊疗方案及中医肝病临床基本术语集，制定肝病结构化电子病历模板集，包括结构化电子病历模板107个，并形成了肝病模板体系表。
3以结构化电子病历为核心，并充分整合医院的信息化资源，包括HIS、LIS、PACS等信息，构建了数字化、信息化、网络化肝病临床科研信息共享系统平台。
第二部分：基于共享系统的慢性乙型肝炎证候规律研究
1慢性乙型肝炎患者基本情况的统计分析，在临床采集的1200例病例中，男性患者922例，占76.8％，女性患者278例，占23.3％，男女比例3.32∶1，说明慢性乙型肝炎患病率男性患者高于女性。年龄分布其中<40岁的患者714例，占59.5％，40-60岁的患者362例，占30.2％，>60岁的患者124例，占10.3％，患病年龄以40岁以下为主。
2慢性乙型肝炎患者中医症状分布，在1200例临床采集病例中，共提取5278个症状，经统计分析，慢性乙型肝炎患者主要症状集中在乏力、烦躁易怒、胁痛、胁胀、口干、口苦、食欲不振、便溏、腹胀、黄疸、小便黄赤等，其中乏力在所有症状中所占比重最高，为65.50％。
3慢性乙型肝炎患者舌脉分布，舌象分布中常见舌质有舌红、舌淡红、舌暗红，其中舌红、舌淡红为主，合计所占比重90％；常见舌苔有苔薄白、苔白、苔薄黄、苔白腻、苔黄腻、苔黄，以苔薄白、苔白为主，所占比重分别为49.83％、21.08％；常见脉象有脉弦、脉缓、脉滑、脉弦细、脉细、脉弦滑、脉数、脉滑数、脉濡，以脉弦最为常见，所占比重68.42％。
4慢性乙型肝炎中医证型分布，共提取慢性乙型肝炎中医证型64个，1200频次，经规范化处理，得出慢性乙型肝炎主要中医证型有：肝郁脾虚证、湿热蕴结证、肝郁气滞证、脾虚湿阻证、瘀血阻络证、肝肾阴虚证、脾肾阳虚证。其中肝郁脾虚证和湿热蕴结证所占比重最大，分别为占53.41％、28.33％。说明肝郁脾虚证和湿热蕴结证是慢性乙型肝炎常见证型。经分析，慢性乙型肝炎中医证型与性别无明显相关性，肝郁脾虚证、湿热蕴结证、肝郁气滞证、脾虚湿阻证与年龄无明显相关性，而瘀血阻络证、肝肾阴虚证、脾肾阳虚证与年龄有一定的相关性。
5对慢性乙型肝炎常见证型肝郁脾虚证和湿热蕴结证进行中医辨证规范化研究，将证型与症状、舌脉进行关联性分析，并结合辨证标准，分析其中医辨证的规范性、准确性，将结果与辨证标准相比较，基本符合规范。
第三部分：基于共享系统的慢性乙型肝炎用药规律研究
1对慢性乙型肝炎总体用药规律分析，得出慢性乙型肝炎最常用的5味中药是茯苓、茵陈、白术、丹参、郁金，其中茯苓应用687频次，占总中药处方比例57.25%；茵陈585频次，占48.75%；白术547频次，占45.58%；丹参488频次，占40.67%；郁金407频次，占33.92%。前20味中药为：茯苓、茵陈、白术、丹参、郁金、白花蛇舌草、连翘、麦芽、甘草、半夏、陈皮、谷芽、柴胡、黄芩、车前草、枳实、薏苡仁、厚朴、赤芍、太子参。从中可以看出慢性乙型肝炎的用药思路是扶正解毒、祛瘀化痰。
2对慢性乙型肝炎中药性味归经的研究，发现常用中药药味以苦味药和甘味药为主，其次是辛味药；中药药性多为性寒、性微寒、性温、性平的中药，并无明显大寒大热竣猛之品，体现了中医“平调阴阳，以平为期”辨证治疗思想；中药归经以归脾经、肝经的中药为主，体现了慢性乙型肝炎从肝脾论治的思想。
3通过对慢性乙型肝炎用药演变规律的分析，显示慢性乙型肝炎的辨证思想从“毒”到“毒痰瘀”再到“毒痰瘀虚”的转变，体现了扶正解毒、祛瘀化痰的治疗思路的形成。结论本研究构建的肝病临床科研信息共享系统，经过临床应用，能满足临床科研的需求，能提高临床医生的工作效率和工作质量，通过对临床数据的结构化标准化存储，能够满足数据挖掘的需求，能够以海量临床信息为基础，开展基于真实世界的临床实际数据的科学研究。初步体现了“以人为中心，以临床数据为导向，从临床中来、到临床中去”临床科研一体化科研范式。基于共享系统对慢性乙型肝炎临床数据进行结构化采集，通过对慢性乙型肝炎中医证候分布特点及辨治用药规律研究，为建立标准化规范化的中医诊疗模式提供参考，为规范慢性乙型肝炎中医辨证论治提供依据。
Background and0bjective
Our country is a high incidence of chronic hepatitis B, whichis widely epidemic and difficult to completely cure, it is estimatedthat more than93,000,000hepatitis B virus carrier in our country,and over20,000,000people has chronic hepatitis B.In which10-20%may develop into hepatic cirrhosis,1-5%can evolve intohepatocellular carcinoma, it is caused huge economic losses and theconsumption of resources, but also posed a serious threat topeople's health and social productivity, it is one of the mostserious public health problems faced by our country. Chinesemedicine is the precious wealth of Chinese people, is thecrystallization of the wisdom of the ancient, is Chinnese mostoriginal field. Strengthen the research on traditional Chinesemedicine in the treatment of chronic hepatitis B, is of greatsignificance to improve our ability of prevention and treatment ofchronic hepatitis B. Chinese medicine treatment in hepatic diseasehas its Chinese medicine theory, and a system with long history,accumulated a large amount of clinical experience. Since60yearsof the last century clinical treatment of Chinese medicine is widely used in the related diseases of hepatitis B virus, and get a lotof the clinical and experimental study with it. The world today isthe age of big data, that is as a great resource, innovation modelto solve the problem by data has been paid attention to more andmore. The large data theory and research method is applied to theclinical and scientific research of TCM, will bring revolutionarychange to traditional Chinese Medicine. In this study, through theconstruction of hepatic disease clinical research informationsharing system,to form the basic information platform ofintegration of clinical research, based on the massive clinicalinformation, to carry out scientific research and clinicalpractice on the data of the real world, then we can find TCMclinical experience, rules and problems, verify the clinical effectof traditional Chinese medicine, find the clinical curative effectof TCM related rules.
In this study, chronic hepatitis B as the research object,analysis of chronic hepatitis B distribution characteristics of TCMsyndromes and syndrome differentiation and treatment of drug rules,to provide reference for the establishment of standardization ofTCM diagnosis and treatment mode, also to provide the basis theoryfor regulating the differentiation of chronic hepatitis B treatment,improving the level of diagnosis and treatment.
Methods: Our study is divided into three partes.Part one:the study on construction of hepatic disease clinicalresearch information sharing system
First, we collect the clinical term from the three basic aspectsof teaching materials, standard, literature, then establish TCMhepatic disease clinical basic term set, formulat structured electronic medical record based on the clinical basic terminologyand hepatic disease in TCM diagnosis and treatment scheme, formatof liver structured electronic medical record template set, fullyintegrated hospital information resources, we use the moderninformation and network technology, to construct the system ofsharing digital, information, network of Chinese medicine clinicaldata supporting platform and management services, called clinicalresearch information sharing system,which has the ability ofwhole clinical information collection, collation and analysis,achieve clinical research based on the real data.Part two: Study on chronic hepatitis B syndrome rule based onsharing system
Based on clinical research information sharing system, wecollect the information of inpatients with chronic hepatitis B byapplicating of structured electronic medical records. The data iscollecting from patients with diagnosis of chronic hepatitis B whoinpatient in the year of2002to2013,a total of1200cases.Analysising, conversing, cleaning, processing the collecting data,and import data that we need into Data warehous. Using theintegration of clinical research technology platform and complexnetwork technology. Analysising the basic information, tongue,pulse and symptoms, TCM syndrome, and the correlation between TCMsyndromes and symptoms, tongue, pulse. SPSS17software is used forstatistical analysis, investigating the regularity of TCMSyndromes of chronic hepatitis B.Part three: Study on chronic hepatitis B syndrome treatment rulebased on sharing system
Based on the information in part two, we analysis the traditional Chinese medicine data, use the clinical researchtechnology integration platform and complex network technology, tostatistical analysis Chinese medicine usage frequency, flavor andmeridian tropism, and analysis the correlation between traditionalChinese medicine and TCM Syndrome. SPSS17software is used forstatistical analysis, investigating the regularity of traditionalChinese medicine of chronic hepatitis B.
Results
Part one:the study on construction of hepatic disease clinicalresearch information sharing system
1.We format criterion standard of TCM hepatic disease clinicalbasic terminology, including26main clinical terms,10propertyterms, in which the common symptoms of hepatic disease terms are69.
2. Base on the hepatic disease in TCM diagnosis and treatmentscheme and TCM hepatic disease clinical basic terminology,we makehepatic structured electronic medical record template set,including107structured electronic medical record template, andformating hepatic template system table.
3. Make structured electronic medical record as the core, wefully integrated hospital information resources, including HIS、LIS、PACS, to construct the digital, information, network ofhepatic disease clinical research information sharing system.Part two: Study on chronic hepatitis B syndrome rule based onsharing system
1.Statistically analysis the basic situation of patients withchronic hepatitis B, in the1200cases from clinical collecting,there is922of male patients, accounted for76.8%;there is278 cases of female patients, accounted for23.3%, male to female ratiois3.32:1, this shows that the rate of male patients of chronichepatitis B was higher than that of female.The age distributionis that aged under40years old patients has714cases, accountedfor59.5%, aged40-60years old patients has362cases, accountedfor30.2%, over60years old patients were124cases, accounted for10.3%, this shows that the age of40years is main.
2.The distribution of TCM symptoms in patients with Chronichepatitis B, in the1200cases from clinical collecting, There were5278symptoms. After statistical analysis, the main symptoms ofpatients with chronic hepatitis B are weakness, irritability, chestpain, flank pain, thirstiness, bitterness, poor appetite, loosestools, jaundice, abdominal distention, yellow urine, et. Theweakness is in the highest proportion of all symptoms, accountedfor65.50%.
3. The distribution of tongue and pulse in patients with Chronichepatitis B, the common tongue of tongue distribution is redtongue, pale tongue, dark red tongue, and red tongue, pale tongueas the main, the total proportion is90%; the common coat of thetongue is thin white fur, white fur, thin yellow fur, white andgreasy fur, yellow greasy fur, yellow fur, and thin white fur, whitefur as the main, the total proportion is49.83%,21.08%; the commonpulse is taut pulse, slow pulse, slippery pulse, wiry pulse, threadypulse, taut and slippery pulse, rapid pulse, slippery and rapidpulse, moisten pulse,and taut pulse as the main.
4. The distribution of TCM syndrome in patients with Chronichepatitis B, we totally extract64TCM Syndrome of chronichepatitis B,1200rates, with standard processing, get the main TCM Syndrome of chronic hepatitis B: syndrome of liver depressionand spleen deficiency, endoretention of damp heat, qi stagnation,spleen deficiency and dampness, blood stasis, liver kidney yindeficiency, spleen kidney yang deficiency syndrome. Among that thebiggest proportion is syndrome of liver depression and spleendeficiency, endoretention of damp heat,each accountedfor53.41%,28.33%.It is show that he main TCM Syndrome is syndromeof liver depression and spleen deficiency, endoretention of dampheat.Through analysising, there is no significant correlationbetween TCM Syndrome patterns of chronic hepatitis B and gender,there is no significant correlation between age and syndrome ofliver depression and spleen deficiency, endoretention of damp heat,qi stagnation, spleen deficiency and dampness,but blood stasis,liver kidney yin deficiency, spleen kidney yang deficiency syndromehas a certain significant correlation with age.
5. We make TCM syndrome differentiation standardization studyon chronic hepatitis B in syndrome of liver depression and spleendeficiency, endoretention of damp heat, do correlated analysis onsyndrome and symptoms, tongue and pulse, combined with syndromedifferentiation standardization,to analysis the standard andaccuracy of TCM syndrome differentiation, comparing the resultswith the standardization, it is basicly specification.Part three: Study on chronic hepatitis B syndrome treatment rulebased on sharing system
1. Analysis of drug rule in chronic hepatitis B, the five mostcommonly used chinese herb for chronic hepatitis B are poria, yinchen, white atractylodes rhizome, radix salviae miltiorrhizae,radix curcumae, and the usage rate of poria is678, accounted for57.25%; yin chen is585, accounted for48.75%, whiteatractylodes rhizome is547, accounted for45.58%, radix salviaemiltiorrhizae is488,accounted for40.67%, radix curcumae is407,accounted for33.92%. The first20using chinese medicinal herbs areporia, yin chen, white atractylodes rhizome, radix salviaemiltiorrhizae, radix curcumae, hedyotis diffusa, forsythia, malt,licorice root, pinellia, dried orange peel, gu ya, bupleurum,scutellaria, plantain, citrus fruit, coix seed, magnolia bark,radix paeoniae rubra, Radix pseudostellariae.We can find thatmedication idea of chronic hepatitis b is the centralizerdetoxification, remove blood stasis phlegm.
2. Study on the tropism and flavour of chinese herb using forchronic hepatitis B, we discover that the common used chinese herbis bitter and sweet, the second is pungent. The property of Chineseherb is cold, slightly cold, warm, flat, but no colder, hot,ferocious medicine, which show the differential treatment thoughtof traditional Chinese medicine "flat to flat-yin and Yang,".Channel tropism in traditional herb is mainly in liver and spleen,it shows the treatment ideas from the liver and spleen in chronichepatitis B.
3. By analyzing the evolution of chronic hepatitis B treatment,shows that the dialectical thought of chronic hepatitis B is fromthe "toxic" to "toxic phlegm and blood stasis" even to "toxic phlegmstasis virtual". Reflecting that the treatment ideas of " thecentralizer detoxification, remove blood stasis phlegm" isformatted.
Conclusions
The construction of hepatic disease clinical research information sharing system in this study,using in clinic, can meetthe demand of clinical research, and can improve the work efficiencyand quality of clinicians. Through structured standardized storagefor clinical data,we can meet the demand of data mining, can makethe massive clinical information as basic, to carry out scientificresearch and clinical practice based on the data of the real world.It is initial manifestation of the "people-centered, clinicaldata-oriented, from clinic to clinic" clinic researchintegration paradigm in clinical research. Sharing system isstructured to collect the clinical data of patients with chronichepatitis B,the distribution regularity of TCM syndromes,differentiation treatment characteristics and drug research inchronic hepatitis B, providing reference for the establishment ofstandardization of TCM diagnosis and treatment mode of chronichepatitis B,providing the basis theory standardization for TCMsyndrome differentiation treatment.
我国是慢性乙型肝炎高发区，其流行性广，难于彻底根治,预计我国有乙肝病毒携带者0.93亿以上,现症慢性乙型肝炎患者约2千万以上,其中10-20%可发展为肝硬化，1-5%可演变为肝癌，不仅造成巨大的经济损失和资源消耗，也给人们的身体健康和社会生产力造成严重威胁，是我国目前面临的最严重的公共卫生问题之一。中医药是我国人民的宝贵财富，是古代人民智慧的结晶，是我国最具原创性的领域。加强中医药防治慢性乙型肝炎的研究，对提高我国慢性乙型肝炎防治能力和水平具有十分重要的意义。中医治疗传统中医肝病有系统的中医理论基础、悠久的历史，积累了大量的临床经验，自从上世纪60年开始中医药就广泛的运用于乙肝病毒引起的相关疾病的临床治疗，并进行了大量的临床与实验研究。当今世界正向大数据时代迈进，数据作为一种巨大的资源，通过数据来解决问题的创新模式已越来越得到重视。将大数据理论及其研究方法应用到中医药的临床与科研中，将会给中医学带来革命性的变化。
本研究通过构建肝病临床科研信息共享系统，形成临床科研一体化的基础信息平台，以海量临床信息为基础，开展基于真实世界的临床实际数据的科学研究，可以从中发现中医临床的经验、规律和问题，验证中医临床疗效，发现中医临床疗效相关的规律。本研究以慢性乙型肝炎为研究对象，分析探讨慢性乙型肝炎中医证候分布特点及辨治用药规律，为建立标准化规范化的中医诊疗模式提供参考，为规范慢性乙型肝炎中医辨证论治提供依据，提高临床诊疗水平。
方法本研究分为三个部分。
第一部分：肝病临床科研信息共享系统构建研究
首先从教材、标准、文献三个方面为基础进行临床术语收集，建立中医肝病临床基本术语集，再基于临床基本术语和肝病中医诊疗方案制定结构化电子病历模板，形成肝病结构化电子病历模板集，并充分整合医院的信息化资源，利用现代信息与网络技术，构建数字化、信息化、网络化的中医药临床数据支撑平台与管理服务共享体系，即临床科研信息共享系统，使其具备临床诊疗信息全程收集、整理和分析能力，实现基于临床实际数据的科学研究。
第二部分：基于共享系统的慢性乙型肝炎证候规律研究
基于临床科研信息共享系统，应用结构化电子病历采集慢性乙型肝炎患者的住院信息。采集数据来源于2002年-2013年诊断为慢性乙型肝炎的住院患者，共1200例。对采集的数据进行解析、转换、清洗、处理，抽取所需要的数据导入数据仓库。利用临床科研一体化技术平台及复杂网络技术，对基本信息、舌象、脉象、症状、中医证候的分布进行聚类分析，对常见证型与症状、舌象、脉象之间进行关联分析，利用SPSS17.0软件进行统计分析，探讨慢性乙型肝炎中医证候分布规律。第三部分：基于共享系统的慢性乙型肝炎用药规律研究
在第二部分的数据采集的基础上将采集的中药数据进行分析处理，利用临床科研一体化技术平台及复杂网络技术，对中药使用频率、药物性味归经等进行了统计分析，并分析中药与中医证候的关联性，利用SPSS17.0软件进行统计分析，探讨慢性乙型肝炎中药用药规律。结果
第一部分：肝病临床科研信息共享系统构建研究
1形成了标准规范的中医肝病临床基本术语集，包括主体临床术语26种，属性术语10种，其中肝病常见症状类术语69个。
2基于中医肝病诊疗方案及中医肝病临床基本术语集，制定肝病结构化电子病历模板集，包括结构化电子病历模板107个，并形成了肝病模板体系表。
3以结构化电子病历为核心，并充分整合医院的信息化资源，包括HIS、LIS、PACS等信息，构建了数字化、信息化、网络化肝病临床科研信息共享系统平台。
第二部分：基于共享系统的慢性乙型肝炎证候规律研究
1慢性乙型肝炎患者基本情况的统计分析，在临床采集的1200例病例中，男性患者922例，占76.8％，女性患者278例，占23.3％，男女比例3.32∶1，说明慢性乙型肝炎患病率男性患者高于女性。年龄分布其中<40岁的患者714例，占59.5％，40-60岁的患者362例，占30.2％，>60岁的患者124例，占10.3％，患病年龄以40岁以下为主。
2慢性乙型肝炎患者中医症状分布，在1200例临床采集病例中，共提取5278个症状，经统计分析，慢性乙型肝炎患者主要症状集中在乏力、烦躁易怒、胁痛、胁胀、口干、口苦、食欲不振、便溏、腹胀、黄疸、小便黄赤等，其中乏力在所有症状中所占比重最高，为65.50％。
3慢性乙型肝炎患者舌脉分布，舌象分布中常见舌质有舌红、舌淡红、舌暗红，其中舌红、舌淡红为主，合计所占比重90％；常见舌苔有苔薄白、苔白、苔薄黄、苔白腻、苔黄腻、苔黄，以苔薄白、苔白为主，所占比重分别为49.83％、21.08％；常见脉象有脉弦、脉缓、脉滑、脉弦细、脉细、脉弦滑、脉数、脉滑数、脉濡，以脉弦最为常见，所占比重68.42％。
4慢性乙型肝炎中医证型分布，共提取慢性乙型肝炎中医证型64个，1200频次，经规范化处理，得出慢性乙型肝炎主要中医证型有：肝郁脾虚证、湿热蕴结证、肝郁气滞证、脾虚湿阻证、瘀血阻络证、肝肾阴虚证、脾肾阳虚证。其中肝郁脾虚证和湿热蕴结证所占比重最大，分别为占53.41％、28.33％。说明肝郁脾虚证和湿热蕴结证是慢性乙型肝炎常见证型。经分析，慢性乙型肝炎中医证型与性别无明显相关性，肝郁脾虚证、湿热蕴结证、肝郁气滞证、脾虚湿阻证与年龄无明显相关性，而瘀血阻络证、肝肾阴虚证、脾肾阳虚证与年龄有一定的相关性。
5对慢性乙型肝炎常见证型肝郁脾虚证和湿热蕴结证进行中医辨证规范化研究，将证型与症状、舌脉进行关联性分析，并结合辨证标准，分析其中医辨证的规范性、准确性，将结果与辨证标准相比较，基本符合规范。
第三部分：基于共享系统的慢性乙型肝炎用药规律研究
1对慢性乙型肝炎总体用药规律分析，得出慢性乙型肝炎最常用的5味中药是茯苓、茵陈、白术、丹参、郁金，其中茯苓应用687频次，占总中药处方比例57.25%；茵陈585频次，占48.75%；白术547频次，占45.58%；丹参488频次，占40.67%；郁金407频次，占33.92%。前20味中药为：茯苓、茵陈、白术、丹参、郁金、白花蛇舌草、连翘、麦芽、甘草、半夏、陈皮、谷芽、柴胡、黄芩、车前草、枳实、薏苡仁、厚朴、赤芍、太子参。从中可以看出慢性乙型肝炎的用药思路是扶正解毒、祛瘀化痰。
2对慢性乙型肝炎中药性味归经的研究，发现常用中药药味以苦味药和甘味药为主，其次是辛味药；中药药性多为性寒、性微寒、性温、性平的中药，并无明显大寒大热竣猛之品，体现了中医“平调阴阳，以平为期”辨证治疗思想；中药归经以归脾经、肝经的中药为主，体现了慢性乙型肝炎从肝脾论治的思想。
3通过对慢性乙型肝炎用药演变规律的分析，显示慢性乙型肝炎的辨证思想从“毒”到“毒痰瘀”再到“毒痰瘀虚”的转变，体现了扶正解毒、祛瘀化痰的治疗思路的形成。结论本研究构建的肝病临床科研信息共享系统，经过临床应用，能满足临床科研的需求，能提高临床医生的工作效率和工作质量，通过对临床数据的结构化标准化存储，能够满足数据挖掘的需求，能够以海量临床信息为基础，开展基于真实世界的临床实际数据的科学研究。初步体现了“以人为中心，以临床数据为导向，从临床中来、到临床中去”临床科研一体化科研范式。基于共享系统对慢性乙型肝炎临床数据进行结构化采集，通过对慢性乙型肝炎中医证候分布特点及辨治用药规律研究，为建立标准化规范化的中医诊疗模式提供参考，为规范慢性乙型肝炎中医辨证论治提供依据。
Background and0bjective
Our country is a high incidence of chronic hepatitis B, whichis widely epidemic and difficult to completely cure, it is estimatedthat more than93,000,000hepatitis B virus carrier in our country,and over20,000,000people has chronic hepatitis B.In which10-20%may develop into hepatic cirrhosis,1-5%can evolve intohepatocellular carcinoma, it is caused huge economic losses and theconsumption of resources, but also posed a serious threat topeople's health and social productivity, it is one of the mostserious public health problems faced by our country. Chinesemedicine is the precious wealth of Chinese people, is thecrystallization of the wisdom of the ancient, is Chinnese mostoriginal field. Strengthen the research on traditional Chinesemedicine in the treatment of chronic hepatitis B, is of greatsignificance to improve our ability of prevention and treatment ofchronic hepatitis B. Chinese medicine treatment in hepatic diseasehas its Chinese medicine theory, and a system with long history,accumulated a large amount of clinical experience. Since60yearsof the last century clinical treatment of Chinese medicine is widely used in the related diseases of hepatitis B virus, and get a lotof the clinical and experimental study with it. The world today isthe age of big data, that is as a great resource, innovation modelto solve the problem by data has been paid attention to more andmore. The large data theory and research method is applied to theclinical and scientific research of TCM, will bring revolutionarychange to traditional Chinese Medicine. In this study, through theconstruction of hepatic disease clinical research informationsharing system,to form the basic information platform ofintegration of clinical research, based on the massive clinicalinformation, to carry out scientific research and clinicalpractice on the data of the real world, then we can find TCMclinical experience, rules and problems, verify the clinical effectof traditional Chinese medicine, find the clinical curative effectof TCM related rules.
In this study, chronic hepatitis B as the research object,analysis of chronic hepatitis B distribution characteristics of TCMsyndromes and syndrome differentiation and treatment of drug rules,to provide reference for the establishment of standardization ofTCM diagnosis and treatment mode, also to provide the basis theoryfor regulating the differentiation of chronic hepatitis B treatment,improving the level of diagnosis and treatment.
Methods: Our study is divided into three partes.Part one:the study on construction of hepatic disease clinicalresearch information sharing system
First, we collect the clinical term from the three basic aspectsof teaching materials, standard, literature, then establish TCMhepatic disease clinical basic term set, formulat structured electronic medical record based on the clinical basic terminologyand hepatic disease in TCM diagnosis and treatment scheme, formatof liver structured electronic medical record template set, fullyintegrated hospital information resources, we use the moderninformation and network technology, to construct the system ofsharing digital, information, network of Chinese medicine clinicaldata supporting platform and management services, called clinicalresearch information sharing system,which has the ability ofwhole clinical information collection, collation and analysis,achieve clinical research based on the real data.Part two: Study on chronic hepatitis B syndrome rule based onsharing system
Based on clinical research information sharing system, wecollect the information of inpatients with chronic hepatitis B byapplicating of structured electronic medical records. The data iscollecting from patients with diagnosis of chronic hepatitis B whoinpatient in the year of2002to2013,a total of1200cases.Analysising, conversing, cleaning, processing the collecting data,and import data that we need into Data warehous. Using theintegration of clinical research technology platform and complexnetwork technology. Analysising the basic information, tongue,pulse and symptoms, TCM syndrome, and the correlation between TCMsyndromes and symptoms, tongue, pulse. SPSS17software is used forstatistical analysis, investigating the regularity of TCMSyndromes of chronic hepatitis B.Part three: Study on chronic hepatitis B syndrome treatment rulebased on sharing system
Based on the information in part two, we analysis the traditional Chinese medicine data, use the clinical researchtechnology integration platform and complex network technology, tostatistical analysis Chinese medicine usage frequency, flavor andmeridian tropism, and analysis the correlation between traditionalChinese medicine and TCM Syndrome. SPSS17software is used forstatistical analysis, investigating the regularity of traditionalChinese medicine of chronic hepatitis B.
Results
Part one:the study on construction of hepatic disease clinicalresearch information sharing system
1.We format criterion standard of TCM hepatic disease clinicalbasic terminology, including26main clinical terms,10propertyterms, in which the common symptoms of hepatic disease terms are69.
2. Base on the hepatic disease in TCM diagnosis and treatmentscheme and TCM hepatic disease clinical basic terminology,we makehepatic structured electronic medical record template set,including107structured electronic medical record template, andformating hepatic template system table.
3. Make structured electronic medical record as the core, wefully integrated hospital information resources, including HIS、LIS、PACS, to construct the digital, information, network ofhepatic disease clinical research information sharing system.Part two: Study on chronic hepatitis B syndrome rule based onsharing system
1.Statistically analysis the basic situation of patients withchronic hepatitis B, in the1200cases from clinical collecting,there is922of male patients, accounted for76.8%;there is278 cases of female patients, accounted for23.3%, male to female ratiois3.32:1, this shows that the rate of male patients of chronichepatitis B was higher than that of female.The age distributionis that aged under40years old patients has714cases, accountedfor59.5%, aged40-60years old patients has362cases, accountedfor30.2%, over60years old patients were124cases, accounted for10.3%, this shows that the age of40years is main.
2.The distribution of TCM symptoms in patients with Chronichepatitis B, in the1200cases from clinical collecting, There were5278symptoms. After statistical analysis, the main symptoms ofpatients with chronic hepatitis B are weakness, irritability, chestpain, flank pain, thirstiness, bitterness, poor appetite, loosestools, jaundice, abdominal distention, yellow urine, et. Theweakness is in the highest proportion of all symptoms, accountedfor65.50%.
3. The distribution of tongue and pulse in patients with Chronichepatitis B, the common tongue of tongue distribution is redtongue, pale tongue, dark red tongue, and red tongue, pale tongueas the main, the total proportion is90%; the common coat of thetongue is thin white fur, white fur, thin yellow fur, white andgreasy fur, yellow greasy fur, yellow fur, and thin white fur, whitefur as the main, the total proportion is49.83%,21.08%; the commonpulse is taut pulse, slow pulse, slippery pulse, wiry pulse, threadypulse, taut and slippery pulse, rapid pulse, slippery and rapidpulse, moisten pulse,and taut pulse as the main.
4. The distribution of TCM syndrome in patients with Chronichepatitis B, we totally extract64TCM Syndrome of chronichepatitis B,1200rates, with standard processing, get the main TCM Syndrome of chronic hepatitis B: syndrome of liver depressionand spleen deficiency, endoretention of damp heat, qi stagnation,spleen deficiency and dampness, blood stasis, liver kidney yindeficiency, spleen kidney yang deficiency syndrome. Among that thebiggest proportion is syndrome of liver depression and spleendeficiency, endoretention of damp heat,each accountedfor53.41%,28.33%.It is show that he main TCM Syndrome is syndromeof liver depression and spleen deficiency, endoretention of dampheat.Through analysising, there is no significant correlationbetween TCM Syndrome patterns of chronic hepatitis B and gender,there is no significant correlation between age and syndrome ofliver depression and spleen deficiency, endoretention of damp heat,qi stagnation, spleen deficiency and dampness,but blood stasis,liver kidney yin deficiency, spleen kidney yang deficiency syndromehas a certain significant correlation with age.
5. We make TCM syndrome differentiation standardization studyon chronic hepatitis B in syndrome of liver depression and spleendeficiency, endoretention of damp heat, do correlated analysis onsyndrome and symptoms, tongue and pulse, combined with syndromedifferentiation standardization,to analysis the standard andaccuracy of TCM syndrome differentiation, comparing the resultswith the standardization, it is basicly specification.Part three: Study on chronic hepatitis B syndrome treatment rulebased on sharing system
1. Analysis of drug rule in chronic hepatitis B, the five mostcommonly used chinese herb for chronic hepatitis B are poria, yinchen, white atractylodes rhizome, radix salviae miltiorrhizae,radix curcumae, and the usage rate of poria is678, accounted for57.25%; yin chen is585, accounted for48.75%, whiteatractylodes rhizome is547, accounted for45.58%, radix salviaemiltiorrhizae is488,accounted for40.67%, radix curcumae is407,accounted for33.92%. The first20using chinese medicinal herbs areporia, yin chen, white atractylodes rhizome, radix salviaemiltiorrhizae, radix curcumae, hedyotis diffusa, forsythia, malt,licorice root, pinellia, dried orange peel, gu ya, bupleurum,scutellaria, plantain, citrus fruit, coix seed, magnolia bark,radix paeoniae rubra, Radix pseudostellariae.We can find thatmedication idea of chronic hepatitis b is the centralizerdetoxification, remove blood stasis phlegm.
2. Study on the tropism and flavour of chinese herb using forchronic hepatitis B, we discover that the common used chinese herbis bitter and sweet, the second is pungent. The property of Chineseherb is cold, slightly cold, warm, flat, but no colder, hot,ferocious medicine, which show the differential treatment thoughtof traditional Chinese medicine "flat to flat-yin and Yang,".Channel tropism in traditional herb is mainly in liver and spleen,it shows the treatment ideas from the liver and spleen in chronichepatitis B.
3. By analyzing the evolution of chronic hepatitis B treatment,shows that the dialectical thought of chronic hepatitis B is fromthe "toxic" to "toxic phlegm and blood stasis" even to "toxic phlegmstasis virtual". Reflecting that the treatment ideas of " thecentralizer detoxification, remove blood stasis phlegm" isformatted.
Conclusions
The construction of hepatic disease clinical research information sharing system in this study,using in clinic, can meetthe demand of clinical research, and can improve the work efficiencyand quality of clinicians. Through structured standardized storagefor clinical data,we can meet the demand of data mining, can makethe massive clinical information as basic, to carry out scientificresearch and clinical practice based on the data of the real world.It is initial manifestation of the "people-centered, clinicaldata-oriented, from clinic to clinic" clinic researchintegration paradigm in clinical research. Sharing system isstructured to collect the clinical data of patients with chronichepatitis B,the distribution regularity of TCM syndromes,differentiation treatment characteristics and drug research inchronic hepatitis B, providing reference for the establishment ofstandardization of TCM diagnosis and treatment mode of chronichepatitis B,providing the basis theory standardization for TCMsyndrome differentiation treatment.
引文
[1]中华医学会肝病学分会、感染病学分会．慢性乙型肝炎防治指南(2010年版）[J]．中国医学前沿杂志（电子版），2011，3(1)：66．
[2]Lu FM,Zhuang H.Mangement of hepatitis B in China. Chin MedJ(Engl),2009,122(1):3-4.
[3]吴朝晖，姜晓红，陈华钧．知识服务：大数据时代下的中医药信息化发展趋势[J]．中国中医药图书情报杂志，2013，37(2):2-5
[4]岳琳哲，施诚．病历、电子病历与中医电子病历[J].医学信息，2006，19(7)：1121-1123
[5]陈衡，黄刊迪．结构化电子病历概述[J].中国数字医学，2011，6（5）：36-39
[6]崔蒙，谢琪等．中医药信息学的内涵及原理研究[J]．浙江中医药大学学报，2009，33(5)：638-641．
[7]崔蒙，李海燕等．“大数据”时代与中医药“知识密集型”数据[J]．中国中医药图书情报杂志，2013，37(3)：1-3.
[8]刘保延，周雪忠等．个体诊疗临床科研信息一体化平台[J].中国数字医学,2007,2（6）：31-33.
[9]Zhou Xuezhong,Chen Shibo,Liu Baoyan.et al.Development oftraditional Chinese medicine clinical data warehouse formedical knowledge discovery and decisionsupport[J]． Artificial Intelligence inMedicine,2010,48:139-152.
[10]刘保延，周雪忠等.“医疗与临床科研信息共享系统”中医电子病历系统信息基本要求[J].中国数字医学,2012,7（10）：57-60.
[11]Ackerman MJ．Big data[J]．J Med Pract Manage，2012，28(2)：153-154．
[12]王震寰．计算医学——应对大数据的挑战向临床转化[J]．蚌埠医学院学报，2014，39(1)：1-2
[13]李平.刘保延等．中医个体诊疗科学研究模式的构想与实践[J]．世界科学技术-中医药现代化，2008，10(4):12.
[14]刘保延.胡镜清等．中医药学现代个体诊疗体系建立的构想与研究[J]．世界科学技术—中医药现代化，2003，5(1):1-5,80.
[15]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社，2002:143-151.
[16]中华中医药学会．中医内科常见病诊疗指南·中医病证部分[M]．北京：中国中医药出版社，2008:89-94.
[17]中华中医药学会．中医内科常见病诊疗指南·西医疾病部分[M]．北京：中国中医药出版社，2008:126-129.
[18]国家技术监督局．中华人民共和国国家标准·中医临床诊疗术语·证候部分(GB/T16751.2-1997)[S]．1997.
[19]朱文锋.中医诊断学[M].北京：中国中医药出版社，2007.
[20]张启明,刘保延,王永炎.中医症状学研究[M].北京：中医古籍出版社,2013.
[21]高学敏.中药学[M].北京：中国中医药出版社,2007.
[22]谢松强,纪忠岐.茵陈提取液对实验性动物肝损伤的作用［J］.医药论坛杂志,2003，24(24):57-59.
[23]宋雨鸿.丹参多糖抗小鼠免疫性肝损伤及其免疫调节机制的研究［D］.南方医科大学,2010.
[24]吕跃山,邢杰,陈英利等.黄芪赤芍对小鼠免疫性肝损伤抗氧化作用的实验研究[J];中华中医药学刊;2008，26(02):302-303.
[25]何小女,易辉亮.白花蛇舌草提取物对肝组织的保护作用［J］.医学信息,2011，24(09):4527-4528.
[26]李秀萍,孙树凯,魏军,等.白花蛇舌草对肝损伤小鼠T细胞亚群、 TNF-A和IL-6的影响［J］.宁夏医学杂志，2010,32(6):495-496.
[27]王胜春，王玲，田卫斌等．柴胡及五灵丸对慢性肝损伤小鼠的影响［J］．第四军医大学学报，2002，23(2)：133-136.
[28]陈爽，贲长恩，杨美娟等．柴胡皂甙对FSC激活及合成细胞外基质的实验研究［J］．北京中医药大学学报，1999，22(1)：31-34.
[29]郑丽娜，韩涛，王宝恩等．柴胡对肝星状细胞胶原蛋白分泌的影响［J］．天津医科大学学报，2001，7(4)：502-503.
[30]高毅，汪爽，詹兴海．柴胡保护大鼠肝脏缺血性损伤［J］．世界华人消化杂志,2000，8(2)：168-170.
[31]胡聪，韩聚强等．黄芩苷对大鼠肝细胞凋亡的影响［J］．中国中药杂志，2001，26(2)：124-127.
[32]蒋幼林．王育群治疗慢性乙肝经验辑要[J]．江西中医药，2002，33(5)：4-5．
[33]陈良金.慢性乙型肝炎辨治十法[J].现代中医药,2003,25(1):54-44.
[34]贵襄平、陈幼坤.乙肝与湿、热、毒、痰、瘀[J].光明中医，2002；17：15-16.
[35]倪云波，范江勇.吴寿善治疗病毒性肝炎经验浅析[J]．湖北中医杂志，2011，33（5）：29.
[36]蔡春江,裴林,李佃贵.伏邪理论在慢性乙型肝炎治疗中的应用[J].浙江中医杂志,2002,37(2):51-52.
[37]王伯祥．慢性乙型肝炎中医药证治研究进展[J]．世界中医药，2007，2(1):61.
[38]王伯祥.中医肝胆病学[M].北京:中国医药科技出版社,1993:203-204.
[39]李瀚旻.论“补肾生髓成肝”治疗法则,中华中医药学刊,2012,30(5):937-940
[40]聂广．王伯祥教授论治乙型肝炎的经验[J]．新中医，1995，（5）：3
[41]张引强，唐旭东等．清利活血健脾法治疗慢性乙型肝炎[J]．辽宁中医杂志，2013，40（8）：1563-1565.
[42]薛博瑜.慢性乙型肝炎中医临证治疗方略[J].药品评价,2009,6(2);74-76.
[43]潘芳.中医治疗慢性乙型病毒性肝炎的研究进展[J].实用中医内科杂志，2010；24(2):74-75.
[44]赵亮，李芳.慢性乙型肝炎从虚、毒、络论治[J].新中医,2008,4O(3);5-6.
[45]盛国光．慢性乙型肝炎的中医病因病机探讨[J]．中西医结合肝病杂志，1997，7(2)：126-127．
[46]盛国光，黄育华等．慢性乙型肝炎中医辨治规律探讨[J]．中西医结合肝病杂志，2012，20(6)：382．
[47]史华新，刘保延等．中医医疗与临床科研信息共享系统数据采集平台服务流构建的思考[J]．中国中医药信息杂志，2013，20(8):4-5
[48]Liu B,Zhou X,Wang Y.et al.Data processing and analysis inreal-world traditional Chinese medicine clinicaldata:challenges and approaches [J]． Stat Med，2012，31(7):653-660
[49]王斌，谢琪等．真实世界临床科研中电子病历数据的存储[J]．中医杂志，2013,54（20）:1736-1738
[50]刘保延，尹爱宁等．中医规范术语在结构化电子病历中应用体系的研究[J]．中国数字医学，2012，7(8):41-44
[51]Grapow MT，von Wattenwyl R，Guller U.et a1．Randomizedcontrolled trials do not reflect reality： real-worldanalyses are critical for treatment guidelines[J]．J ThoracCardiovasc Surg，2006．132(1)：5-7．
[52]Knottnerus JA， Tugwell E.Real world research． J ClinEpidemiol,2010．63(10)：105I-1052．
[53]Williamson TR，Barrett GV．Feasibility of measuring eyemovements in real-world and simulated drivingsituations．Percept Mot Skills．1966，23(1)：329-330．
[54]Kaplan NM，Sproul LE，Mulcahy WS．Large prospective studyof ramipril in patients with hypertension． CAREInvestigators．Chin Ther．1993，15(5)：810-818．
[55]刘保延．真实世界的中医临床科研范式[J]．中医杂志，2013，54(6)：452-455．
[1] Ganem D, Prince AM. Hepatitis B virus infection--naturalhistory and clinical consequences[J]. N Engl J Med,2004,350:1118-1129.
[2] World Health Organization. Hepatitis B (Revised August2008)[EB/OL].[2010-12-9].http://www.who.int/mediacentre/factsheets/fs204/en/.
[3]中华医学会肝病学分会、感染病学分会．慢性乙型肝炎防治指南(2010年版）[J]．中国医学前沿杂志（电子版），2011，3（1）：66．
[4] Lu FM,Zhuang H.Mangement of hepatitis B in China. Chin MedJ(Engl),2009,122(1):3-4.
[5]盛国光．慢性乙型肝炎的中医病因病机探讨[J]．中西医结合肝病杂志，1997，7(2)：126-127．
[6]盛国光，黄育华等．慢性乙型肝炎中医辨治规律探讨[J]．中西医结合肝病杂志，2012，20(6)：382．
[7]裴建宏,王灵台.辨治慢性乙型肝炎经验[J].安徽中医临床杂志,2002,14(6):432-433.
[8]倪云波，范江勇.吴寿善治疗病毒性肝炎经验浅析[J]．湖北中医杂志，2011，33（5）：29.
[9]蔡春江,裴林,李佃贵.伏邪理论在慢性乙型肝炎治疗中的应用[J].浙江中医杂志,2002,37(2):51-52.
[10]贵襄平、陈幼坤.乙肝与湿、热、毒、痰、瘀[J].光明中医，2002；17：15-16.
[11]陈良金.慢性乙型肝炎辨治十法[J].现代中医药,2003,25(1):54-44.
[12]潘芳.中医治疗慢性乙型病毒性肝炎的研究进展[J].实用中医内科杂志，2010；24(2):74-75.
[13]叶永安，江锋，赵志敏等.慢性乙型肝炎中医证型分布规律研究.中医杂志[J],2007,48(3)：256-258.
[14]中国中医药学会肝病专业委员会，病毒性肝炎中医辨证标准（试行），2004.
[15]吕文良.慢性乙型肝炎中医证型的探讨[J].中国中医基础医学杂志,2008;14(7):525-527.
[16]刘金霞,麻晓慧.对慢性乙型肝炎证候复杂性的再认识[J].中国中医药信息杂志,2004,11(4):364.
[17]高月求，王灵台，慢性乙型肝炎中医证型研究探讨[J].中国中医基础医学杂志,2003,9(8):40-41.
[18]王凤云等．慢性乙型肝炎患者中医证型特点及分布差异[J]．世界华人消化杂志，2008；16(7)：716-720.
[19]Wei HF，Ya BL，Zhao L，Ye CF，Zhang L，Li L．Evaluation of tonguemanifestation of blood stasis syndrome and its relationshipwith blood rheological disorder in a rat model of transientbrain ischemia[J]．Zhongxiyi jiehe Xuebao，2008；6：73-76.
[20]盛桂琴，徐秀梅．AST、AL T及AST／ALT与慢性乙型肝炎中医证型关系探讨[J].江西中医药,2006，37(1)：21
[21]古伟明等.慢性乙型肝炎中医证型与相关性实验指标关系[J],广州医药，2012；43（1）:42-45
[22]莫让辉等.慢性肝炎中医证型与肝组织病理变化的关系[J].辽宁中医杂志，2006,33（8）:918.
[23]张国良，吴其恺，林巧，等．260例慢性乙型肝炎中医证型与肝组织病理改变的相关性研究[J]．中国中西医结合杂志，2007，27(7)：613-614．
[24]王振常等.慢性乙型肝炎中医证型与免疫功能关系的初步研究[J].广西中医药，2009，32（4）：195-196.
[25]王见义，韩向晖，王灵台，等．慢性乙型肝炎中医证型与免疫功能的相关性研究[J]．上海中医药杂志，2007，41(9)：35-36．
[26]田代华.黄帝内经素问[M].北京：人民卫生出版社，2005.
[27]张家礼.金匮要略[M].北京：中国中医药出版社，2004:19.
[28]薛博瑜.慢性乙型肝炎中医临证治疗方略[J].药品评价,2009,6(2);74-76.
[29]赵亮，李芳.慢性乙型肝炎从虚、毒、络论治[J].新中医,2008,4O(3);5-6.
[30]郝红燕，梁瑞敏.中药治疗慢性乙型病毒性肝炎的体会[J].山西职工医学院学报，2008，18（2）；67-68.
[31]杨毅勇，陆菁.中医养阴柔肝化湿解毒方治疗慢性乙型肝炎疗效观察[J].同济大学学报(医学版),2011,32(6);100-102.
[32]边文贵.袁今奇.扶正祛邪调肝方治疗慢性乙型肝炎128例[J]．四川中医,2005;23(8):52-53.
[33]蒋健.关于中医肝病学术的若干思考[J].中西医结合肝病杂志,2005,15(2）：65-67.
[34]Patrick DL．Patient-reported outcomes(PR0s)：an organizingtool for concepts，measures and applications．Qual LifeNewsletter，2003：31：1-5．
[35]刘凤斌.量表测评方法在中医临床疗效评价中的应用与展望[J].中国中西医结合杂志，2007，27（12）：1129-1132.
[36]保志军，邱德凯，马雄.慢性肝病的生命质量量表评价[J].肝脏，2008，13（4）：332-333.
[37]Yacavone RF，Locke GR3rd，Provenzale DT，et a1．Quality of lifemeasurement in gastroenterology：what is available? Am JGastroenterol，2001，96：285—297．
[38]郭志忠.蒋健.苏式兵.中医临床疗效方法探讨[J].世界科学技术一中医药现代化,2009,11(5):653-658
[39]魏华风，郑培永，季光．中医临床疗效评价的思路与方法[J].中西医结合学报，2005，3(3)：184～190．
[40]Grapow MT，von Wattenwyl R，Guller U.et a1．Randomized controlledtrials do not reflect reality：real-world analyses are criticalfor treatment guidelines[J].J Thorac Cardiovasc Surg，2006．132(1)：5-7．
[41]Knottnerus JA， Tugwell E.Real world research． J ClinEpidemiol,2010．63(10)：105I-1052．
[42]Williamson TR， Barrett GV． Feasibility of measuring eyemovements in real-world and simulated drivingsituations．Percept Mot Skills．1966，23(1)：329-330．
[43]Kaplan NM，Sproul LE，Mulcahy WS．Large prospective study oframipril in patients with hypertension． CAREInvestigators．Chin Ther．1993，15(5)：810-818．
[44]李敏，时景璞，于慧会.真实世界研究与随机对照试验、单病例随机对照试验在临床治疗性研究中的关系比较[J].中华流行病学杂志，2012，33（3）：342-345
[45]von Elm E．Altman DG，Egger M，et a1．The Strengthening theReporting of Observational Studies in Epidemiology(STROBE)statement：guidelines for reporting observational studies．JClin Epidemiol，2008，61(4)：344-349．
[46]Tian F，Xie YM．Real-world study：a potential new approach toeffectiveness evaluation of traditionaI Chinese medicineinterventions．J Chin Integr Med．2010；8(4)：301-306．(in Chinese)田峰，谢雁鸣．真实世界研究：中医干预措施效果评价的新理念．中西医结合学报．2010．8(4)：301—306．
[47]TMushlin AI, Ghomrawi H. Health care reform and the need forcomparative-effectiveness research [J]. N Engl J Med,2010,362(3):6.
[48]Tunis S, Benner J, McClellan M. Coparative effectivenessresearch：methods development and research infrastructure[J].Stat Med,2010,29(19)：1963-1976.
[49]Aickin M. Comparative effectiveness research and CAM. J AlternComplement Med.2010;16(1):1-2.
[50]谢雁鸣,廖星,王永炎.将比较效益研究理念引入中医临床评价研究.中西医结合学报，2011;9(8):813-818.
[51]Center for Medical Technology Policy. Comparativeeffectiveness definitions.(2008)[2011-05-16].
[52]Federal Coordinating Council for Comparative EffectivenessResearch. Report to the President and the Congress.(2009-06-30)[2011-05-16].
[53]Witt CM. Clinical research efficacy on acupuncture一Conceptsand guidance on efficacy and effectiveness research. Chin JIntegr Med.2011;17(3):166-172.
[54]曹红波，商洪才.比较效果研究的内涵和外延及其用于中医临床评价的可行性分析[J].中西医结合学报，2012，10(4),369-373.
[55]胡善联.美国奥巴马政府医疗改革的特点及其措施[J].卫生经济研究，2009，7:9-10.
[2]Lu FM,Zhuang H.Mangement of hepatitis B in China. Chin MedJ(Engl),2009,122(1):3-4.
[3]吴朝晖，姜晓红，陈华钧．知识服务：大数据时代下的中医药信息化发展趋势[J]．中国中医药图书情报杂志，2013，37(2):2-5
[4]岳琳哲，施诚．病历、电子病历与中医电子病历[J].医学信息，2006，19(7)：1121-1123
[5]陈衡，黄刊迪．结构化电子病历概述[J].中国数字医学，2011，6（5）：36-39
[6]崔蒙，谢琪等．中医药信息学的内涵及原理研究[J]．浙江中医药大学学报，2009，33(5)：638-641．
[7]崔蒙，李海燕等．“大数据”时代与中医药“知识密集型”数据[J]．中国中医药图书情报杂志，2013，37(3)：1-3.
[8]刘保延，周雪忠等．个体诊疗临床科研信息一体化平台[J].中国数字医学,2007,2（6）：31-33.
[9]Zhou Xuezhong,Chen Shibo,Liu Baoyan.et al.Development oftraditional Chinese medicine clinical data warehouse formedical knowledge discovery and decisionsupport[J]． Artificial Intelligence inMedicine,2010,48:139-152.
[10]刘保延，周雪忠等.“医疗与临床科研信息共享系统”中医电子病历系统信息基本要求[J].中国数字医学,2012,7（10）：57-60.
[11]Ackerman MJ．Big data[J]．J Med Pract Manage，2012，28(2)：153-154．
[12]王震寰．计算医学——应对大数据的挑战向临床转化[J]．蚌埠医学院学报，2014，39(1)：1-2
[13]李平.刘保延等．中医个体诊疗科学研究模式的构想与实践[J]．世界科学技术-中医药现代化，2008，10(4):12.
[14]刘保延.胡镜清等．中医药学现代个体诊疗体系建立的构想与研究[J]．世界科学技术—中医药现代化，2003，5(1):1-5,80.
[15]郑筱萸.中药新药临床研究指导原则.北京:中国医药科技出版社，2002:143-151.
[16]中华中医药学会．中医内科常见病诊疗指南·中医病证部分[M]．北京：中国中医药出版社，2008:89-94.
[17]中华中医药学会．中医内科常见病诊疗指南·西医疾病部分[M]．北京：中国中医药出版社，2008:126-129.
[18]国家技术监督局．中华人民共和国国家标准·中医临床诊疗术语·证候部分(GB/T16751.2-1997)[S]．1997.
[19]朱文锋.中医诊断学[M].北京：中国中医药出版社，2007.
[20]张启明,刘保延,王永炎.中医症状学研究[M].北京：中医古籍出版社,2013.
[21]高学敏.中药学[M].北京：中国中医药出版社,2007.
[22]谢松强,纪忠岐.茵陈提取液对实验性动物肝损伤的作用［J］.医药论坛杂志,2003，24(24):57-59.
[23]宋雨鸿.丹参多糖抗小鼠免疫性肝损伤及其免疫调节机制的研究［D］.南方医科大学,2010.
[24]吕跃山,邢杰,陈英利等.黄芪赤芍对小鼠免疫性肝损伤抗氧化作用的实验研究[J];中华中医药学刊;2008，26(02):302-303.
[25]何小女,易辉亮.白花蛇舌草提取物对肝组织的保护作用［J］.医学信息,2011，24(09):4527-4528.
[26]李秀萍,孙树凯,魏军,等.白花蛇舌草对肝损伤小鼠T细胞亚群、 TNF-A和IL-6的影响［J］.宁夏医学杂志，2010,32(6):495-496.
[27]王胜春，王玲，田卫斌等．柴胡及五灵丸对慢性肝损伤小鼠的影响［J］．第四军医大学学报，2002，23(2)：133-136.
[28]陈爽，贲长恩，杨美娟等．柴胡皂甙对FSC激活及合成细胞外基质的实验研究［J］．北京中医药大学学报，1999，22(1)：31-34.
[29]郑丽娜，韩涛，王宝恩等．柴胡对肝星状细胞胶原蛋白分泌的影响［J］．天津医科大学学报，2001，7(4)：502-503.
[30]高毅，汪爽，詹兴海．柴胡保护大鼠肝脏缺血性损伤［J］．世界华人消化杂志,2000，8(2)：168-170.
[31]胡聪，韩聚强等．黄芩苷对大鼠肝细胞凋亡的影响［J］．中国中药杂志，2001，26(2)：124-127.
[32]蒋幼林．王育群治疗慢性乙肝经验辑要[J]．江西中医药，2002，33(5)：4-5．
[33]陈良金.慢性乙型肝炎辨治十法[J].现代中医药,2003,25(1):54-44.
[34]贵襄平、陈幼坤.乙肝与湿、热、毒、痰、瘀[J].光明中医，2002；17：15-16.
[35]倪云波，范江勇.吴寿善治疗病毒性肝炎经验浅析[J]．湖北中医杂志，2011，33（5）：29.
[36]蔡春江,裴林,李佃贵.伏邪理论在慢性乙型肝炎治疗中的应用[J].浙江中医杂志,2002,37(2):51-52.
[37]王伯祥．慢性乙型肝炎中医药证治研究进展[J]．世界中医药，2007，2(1):61.
[38]王伯祥.中医肝胆病学[M].北京:中国医药科技出版社,1993:203-204.
[39]李瀚旻.论“补肾生髓成肝”治疗法则,中华中医药学刊,2012,30(5):937-940
[40]聂广．王伯祥教授论治乙型肝炎的经验[J]．新中医，1995，（5）：3
[41]张引强，唐旭东等．清利活血健脾法治疗慢性乙型肝炎[J]．辽宁中医杂志，2013，40（8）：1563-1565.
[42]薛博瑜.慢性乙型肝炎中医临证治疗方略[J].药品评价,2009,6(2);74-76.
[43]潘芳.中医治疗慢性乙型病毒性肝炎的研究进展[J].实用中医内科杂志，2010；24(2):74-75.
[44]赵亮，李芳.慢性乙型肝炎从虚、毒、络论治[J].新中医,2008,4O(3);5-6.
[45]盛国光．慢性乙型肝炎的中医病因病机探讨[J]．中西医结合肝病杂志，1997，7(2)：126-127．
[46]盛国光，黄育华等．慢性乙型肝炎中医辨治规律探讨[J]．中西医结合肝病杂志，2012，20(6)：382．
[47]史华新，刘保延等．中医医疗与临床科研信息共享系统数据采集平台服务流构建的思考[J]．中国中医药信息杂志，2013，20(8):4-5
[48]Liu B,Zhou X,Wang Y.et al.Data processing and analysis inreal-world traditional Chinese medicine clinicaldata:challenges and approaches [J]． Stat Med，2012，31(7):653-660
[49]王斌，谢琪等．真实世界临床科研中电子病历数据的存储[J]．中医杂志，2013,54（20）:1736-1738
[50]刘保延，尹爱宁等．中医规范术语在结构化电子病历中应用体系的研究[J]．中国数字医学，2012，7(8):41-44
[51]Grapow MT，von Wattenwyl R，Guller U.et a1．Randomizedcontrolled trials do not reflect reality： real-worldanalyses are critical for treatment guidelines[J]．J ThoracCardiovasc Surg，2006．132(1)：5-7．
[52]Knottnerus JA， Tugwell E.Real world research． J ClinEpidemiol,2010．63(10)：105I-1052．
[53]Williamson TR，Barrett GV．Feasibility of measuring eyemovements in real-world and simulated drivingsituations．Percept Mot Skills．1966，23(1)：329-330．
[54]Kaplan NM，Sproul LE，Mulcahy WS．Large prospective studyof ramipril in patients with hypertension． CAREInvestigators．Chin Ther．1993，15(5)：810-818．
[55]刘保延．真实世界的中医临床科研范式[J]．中医杂志，2013，54(6)：452-455．
[1] Ganem D, Prince AM. Hepatitis B virus infection--naturalhistory and clinical consequences[J]. N Engl J Med,2004,350:1118-1129.
[2] World Health Organization. Hepatitis B (Revised August2008)[EB/OL].[2010-12-9].http://www.who.int/mediacentre/factsheets/fs204/en/.
[3]中华医学会肝病学分会、感染病学分会．慢性乙型肝炎防治指南(2010年版）[J]．中国医学前沿杂志（电子版），2011，3（1）：66．
[4] Lu FM,Zhuang H.Mangement of hepatitis B in China. Chin MedJ(Engl),2009,122(1):3-4.
[5]盛国光．慢性乙型肝炎的中医病因病机探讨[J]．中西医结合肝病杂志，1997，7(2)：126-127．
[6]盛国光，黄育华等．慢性乙型肝炎中医辨治规律探讨[J]．中西医结合肝病杂志，2012，20(6)：382．
[7]裴建宏,王灵台.辨治慢性乙型肝炎经验[J].安徽中医临床杂志,2002,14(6):432-433.
[8]倪云波，范江勇.吴寿善治疗病毒性肝炎经验浅析[J]．湖北中医杂志，2011，33（5）：29.
[9]蔡春江,裴林,李佃贵.伏邪理论在慢性乙型肝炎治疗中的应用[J].浙江中医杂志,2002,37(2):51-52.
[10]贵襄平、陈幼坤.乙肝与湿、热、毒、痰、瘀[J].光明中医，2002；17：15-16.
[11]陈良金.慢性乙型肝炎辨治十法[J].现代中医药,2003,25(1):54-44.
[12]潘芳.中医治疗慢性乙型病毒性肝炎的研究进展[J].实用中医内科杂志，2010；24(2):74-75.
[13]叶永安，江锋，赵志敏等.慢性乙型肝炎中医证型分布规律研究.中医杂志[J],2007,48(3)：256-258.
[14]中国中医药学会肝病专业委员会，病毒性肝炎中医辨证标准（试行），2004.
[15]吕文良.慢性乙型肝炎中医证型的探讨[J].中国中医基础医学杂志,2008;14(7):525-527.
[16]刘金霞,麻晓慧.对慢性乙型肝炎证候复杂性的再认识[J].中国中医药信息杂志,2004,11(4):364.
[17]高月求，王灵台，慢性乙型肝炎中医证型研究探讨[J].中国中医基础医学杂志,2003,9(8):40-41.
[18]王凤云等．慢性乙型肝炎患者中医证型特点及分布差异[J]．世界华人消化杂志，2008；16(7)：716-720.
[19]Wei HF，Ya BL，Zhao L，Ye CF，Zhang L，Li L．Evaluation of tonguemanifestation of blood stasis syndrome and its relationshipwith blood rheological disorder in a rat model of transientbrain ischemia[J]．Zhongxiyi jiehe Xuebao，2008；6：73-76.
[20]盛桂琴，徐秀梅．AST、AL T及AST／ALT与慢性乙型肝炎中医证型关系探讨[J].江西中医药,2006，37(1)：21
[21]古伟明等.慢性乙型肝炎中医证型与相关性实验指标关系[J],广州医药，2012；43（1）:42-45
[22]莫让辉等.慢性肝炎中医证型与肝组织病理变化的关系[J].辽宁中医杂志，2006,33（8）:918.
[23]张国良，吴其恺，林巧，等．260例慢性乙型肝炎中医证型与肝组织病理改变的相关性研究[J]．中国中西医结合杂志，2007，27(7)：613-614．
[24]王振常等.慢性乙型肝炎中医证型与免疫功能关系的初步研究[J].广西中医药，2009，32（4）：195-196.
[25]王见义，韩向晖，王灵台，等．慢性乙型肝炎中医证型与免疫功能的相关性研究[J]．上海中医药杂志，2007，41(9)：35-36．
[26]田代华.黄帝内经素问[M].北京：人民卫生出版社，2005.
[27]张家礼.金匮要略[M].北京：中国中医药出版社，2004:19.
[28]薛博瑜.慢性乙型肝炎中医临证治疗方略[J].药品评价,2009,6(2);74-76.
[29]赵亮，李芳.慢性乙型肝炎从虚、毒、络论治[J].新中医,2008,4O(3);5-6.
[30]郝红燕，梁瑞敏.中药治疗慢性乙型病毒性肝炎的体会[J].山西职工医学院学报，2008，18（2）；67-68.
[31]杨毅勇，陆菁.中医养阴柔肝化湿解毒方治疗慢性乙型肝炎疗效观察[J].同济大学学报(医学版),2011,32(6);100-102.
[32]边文贵.袁今奇.扶正祛邪调肝方治疗慢性乙型肝炎128例[J]．四川中医,2005;23(8):52-53.
[33]蒋健.关于中医肝病学术的若干思考[J].中西医结合肝病杂志,2005,15(2）：65-67.
[34]Patrick DL．Patient-reported outcomes(PR0s)：an organizingtool for concepts，measures and applications．Qual LifeNewsletter，2003：31：1-5．
[35]刘凤斌.量表测评方法在中医临床疗效评价中的应用与展望[J].中国中西医结合杂志，2007，27（12）：1129-1132.
[36]保志军，邱德凯，马雄.慢性肝病的生命质量量表评价[J].肝脏，2008，13（4）：332-333.
[37]Yacavone RF，Locke GR3rd，Provenzale DT，et a1．Quality of lifemeasurement in gastroenterology：what is available? Am JGastroenterol，2001，96：285—297．
[38]郭志忠.蒋健.苏式兵.中医临床疗效方法探讨[J].世界科学技术一中医药现代化,2009,11(5):653-658
[39]魏华风，郑培永，季光．中医临床疗效评价的思路与方法[J].中西医结合学报，2005，3(3)：184～190．
[40]Grapow MT，von Wattenwyl R，Guller U.et a1．Randomized controlledtrials do not reflect reality：real-world analyses are criticalfor treatment guidelines[J].J Thorac Cardiovasc Surg，2006．132(1)：5-7．
[41]Knottnerus JA， Tugwell E.Real world research． J ClinEpidemiol,2010．63(10)：105I-1052．
[42]Williamson TR， Barrett GV． Feasibility of measuring eyemovements in real-world and simulated drivingsituations．Percept Mot Skills．1966，23(1)：329-330．
[43]Kaplan NM，Sproul LE，Mulcahy WS．Large prospective study oframipril in patients with hypertension． CAREInvestigators．Chin Ther．1993，15(5)：810-818．
[44]李敏，时景璞，于慧会.真实世界研究与随机对照试验、单病例随机对照试验在临床治疗性研究中的关系比较[J].中华流行病学杂志，2012，33（3）：342-345
[45]von Elm E．Altman DG，Egger M，et a1．The Strengthening theReporting of Observational Studies in Epidemiology(STROBE)statement：guidelines for reporting observational studies．JClin Epidemiol，2008，61(4)：344-349．
[46]Tian F，Xie YM．Real-world study：a potential new approach toeffectiveness evaluation of traditionaI Chinese medicineinterventions．J Chin Integr Med．2010；8(4)：301-306．(in Chinese)田峰，谢雁鸣．真实世界研究：中医干预措施效果评价的新理念．中西医结合学报．2010．8(4)：301—306．
[47]TMushlin AI, Ghomrawi H. Health care reform and the need forcomparative-effectiveness research [J]. N Engl J Med,2010,362(3):6.
[48]Tunis S, Benner J, McClellan M. Coparative effectivenessresearch：methods development and research infrastructure[J].Stat Med,2010,29(19)：1963-1976.
[49]Aickin M. Comparative effectiveness research and CAM. J AlternComplement Med.2010;16(1):1-2.
[50]谢雁鸣,廖星,王永炎.将比较效益研究理念引入中医临床评价研究.中西医结合学报，2011;9(8):813-818.
[51]Center for Medical Technology Policy. Comparativeeffectiveness definitions.(2008)[2011-05-16].
[52]Federal Coordinating Council for Comparative EffectivenessResearch. Report to the President and the Congress.(2009-06-30)[2011-05-16].
[53]Witt CM. Clinical research efficacy on acupuncture一Conceptsand guidance on efficacy and effectiveness research. Chin JIntegr Med.2011;17(3):166-172.
[54]曹红波，商洪才.比较效果研究的内涵和外延及其用于中医临床评价的可行性分析[J].中西医结合学报，2012，10(4),369-373.
[55]胡善联.美国奥巴马政府医疗改革的特点及其措施[J].卫生经济研究，2009，7:9-10.